Official poster for the Neuroblastoma Treatment Progress and Academic Heritage Exchange Conference on August 8, 2026
Understanding Neuroblastoma
Neuroblastoma is often called the "king of pediatric tumors." It is the most common extracranial solid tumor in infants and young children, arising from immature nerve cells. For decades, high-risk neuroblastoma has remained one of the most challenging diseases in pediatric oncology, requiring advanced multidisciplinary care and innovative therapies.
Conference Overview
Neuroblastoma Treatment Progress and Academic Heritage Exchange Conference
A Forty-Year Legacy of Low-Dose Induction Differentiation Therapy
The conference will systematically review forty years of clinical experience in treating neuroblastoma with low-dose induction differentiation therapy. Experts will explore the theoretical foundation, clinical practice, and long-term follow-up outcomes of this approach, demonstrating how decades of accumulated wisdom have shaped modern treatment strategies.
In addition to honoring this important academic legacy, the meeting will focus on the latest advances in neuroblastoma care, including:
- Induction differentiation therapy: Principles and refined protocols for low-dose differentiation agents.
- Targeted therapy: Molecular targets and precision treatment options for high-risk patients.
- Immunotherapy: Integration of immune-based treatments into clinical practice.
- Multidisciplinary innovation: Combining surgery, chemotherapy, radiotherapy, and supportive care for optimal outcomes.
Jingdu's Invitation: We sincerely invite colleagues from across the field of pediatric oncology to join us in witnessing this important moment of academic heritage. May forty years of wisdom illuminate the future for more children and families affected by neuroblastoma.
